First Amendment to Chromocell Therapeutics Corporation 2023 Equity Incentive Plan
This amendment, adopted by the Board of Directors of Chromocell Therapeutics Corporation, increases the number of shares available under the company's 2023 Equity Incentive Plan from 3,000,000 to 4,000,000. All other terms and conditions of the original plan remain unchanged. The amendment is effective as of September 2023.
Exhibit 10.12
FIRST AMENDMENT TO THE CHROMOCELL THERAPEUTICS CORPORATION
2023 EQUITY INCENTIVE PLAN
______________________________________________
As adopted by resolution of the
Board of Directors effective as of [September __, 2023]
______________________________________________
1. Section 3 of the Chromocell Therapeutics Corporation 2023 Equity Incentive Plan (the “2023 Plan”) is amended by deleting the number “3,000,000” and inserting therefor “4,000,000.”
2. Except as hereinabove amended, the provisions of the 2023 Plan shall remain in full force and effect.
| 1 |
